Camrelizumab Biosimilar

Camrelizumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting PDCD1/PD-1/CD279, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications.

Camrelizumab is under investigation in clinical trial NCT03417895 (SHR-1210 Combined With Apatinib in Treatment of ED-SCLC After Failure of First Line Standard Therapy).

Target	PDCD1/PD-1/CD279
Research Area	Humanized Monoclonal Antibodies, Biosimilars
Clonality	Monoclonal
Reactivity	Human
Expression	Recombinant
Tested Applications	ELISA
Host	Human
Recommended dilutions	Optimal dilutions/concentrations should be determined by the end user.
Conjugation	Unconjugated
Isotype	IgG4 Kappa
Form	Liquid
Purity	> 95%
Purification	Purified from cell culture supernatants by Protein A/G chromatography.
Storage	Store at 4°C for up to 2 weeks. Aliquot and store at -20°C for long term storage. Avoid repeated freeze/thaw cycles.
Shelf Life	12 months.
Buffer	0.01 M PBS, pH 7.4.
CAS Number	1798286-48-2
Concentration	Batch-dependent, typically between 0.5-2.0 mg/ml.
Availability	Shipped within 5-10 working days.
Note	THIS PRODUCT IS FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC, THERAPEUTIC OR COSMETIC PROCEDURES. NOT FOR HUMAN OR ANIMAL CONSUMPTION.

Research Articles on PDCD1/PD-1/CD279

Write a review

Your Name

Your Email Address

PMID

DOI

Your Review

Rating

Continue